EA200970239A1 - TITING REGIME OF BIFEPRUNOX FOR THE TREATMENT OF SCHIZOPHRENIA AND KITS FOR APPLICATION IN THIS AREA - Google Patents

TITING REGIME OF BIFEPRUNOX FOR THE TREATMENT OF SCHIZOPHRENIA AND KITS FOR APPLICATION IN THIS AREA

Info

Publication number
EA200970239A1
EA200970239A1 EA200970239A EA200970239A EA200970239A1 EA 200970239 A1 EA200970239 A1 EA 200970239A1 EA 200970239 A EA200970239 A EA 200970239A EA 200970239 A EA200970239 A EA 200970239A EA 200970239 A1 EA200970239 A1 EA 200970239A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bifeprunox
treatment
titing
schizophrenia
regime
Prior art date
Application number
EA200970239A
Other languages
Russian (ru)
Inventor
Антье А. Винсемиус
Питер В.А.Й. Ван Ден Брук
Луиджи М. Барбато
Original Assignee
Солвей Фармасьютикалс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Солвей Фармасьютикалс Б.В. filed Critical Солвей Фармасьютикалс Б.В.
Publication of EA200970239A1 publication Critical patent/EA200970239A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Abstract

Настоящее изобретение направлено на применение соединения бифепрунокса для набора для титрования для режима титрования, чтобы облегчить начало лечения приблизительно одного из состояний или расстройств центральной нервной системы (ЦНС) при помощи введения множества дозировок состава, содержащего соединение 7-[4-([1,1'-бифенил]-3-ильметил)-1-пиперазинил]-2(3Н)-бензоксазолон (МНН бифепрунокс).The present invention is directed to the use of a bifeprunox compound for a titration kit for a titration regimen to facilitate the initiation of treatment of approximately one of a condition or disorder of the central nervous system (CNS) by administering multiple dosages of a composition containing compound 7- [4 - ([1,1 '-biphenyl] -3-ylmethyl) -1-piperazinyl] -2 (3H) benzoxazolone (INN bifeprunox).

EA200970239A 2006-08-31 2007-08-29 TITING REGIME OF BIFEPRUNOX FOR THE TREATMENT OF SCHIZOPHRENIA AND KITS FOR APPLICATION IN THIS AREA EA200970239A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84124406P 2006-08-31 2006-08-31
EP06119936 2006-08-31
US84149506P 2006-09-01 2006-09-01
EP06120016 2006-09-01
PCT/EP2007/058957 WO2008025780A1 (en) 2006-08-31 2007-08-29 Titration schedule for bifeprunox for treating schizophrenia and kits for use therein

Publications (1)

Publication Number Publication Date
EA200970239A1 true EA200970239A1 (en) 2009-08-28

Family

ID=38704953

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970239A EA200970239A1 (en) 2006-08-31 2007-08-29 TITING REGIME OF BIFEPRUNOX FOR THE TREATMENT OF SCHIZOPHRENIA AND KITS FOR APPLICATION IN THIS AREA

Country Status (10)

Country Link
EP (2) EP2059245A1 (en)
JP (2) JP2010501626A (en)
KR (1) KR20090063228A (en)
AU (2) AU2007291234A1 (en)
BR (1) BRPI0715445A2 (en)
CA (2) CA2661120A1 (en)
EA (1) EA200970239A1 (en)
IL (1) IL196867A0 (en)
NO (1) NO20091243L (en)
WO (2) WO2008025780A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060742A1 (en) * 2008-11-03 2010-06-03 Solvay Pharmaceuticals B.V. Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders
WO2010070061A1 (en) * 2008-12-19 2010-06-24 Abbott Healthcare Products B.V. Compositions, kits and methods of a titration schedule for bifeprunox compounds
LT2445502T (en) 2009-06-25 2017-09-25 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
EP3718536A1 (en) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
MA39495A (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Ltd ARIIPIPRAZOLE FORMULATIONS WITH HIGHER INJECTION RATES
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT889889E (en) * 1996-03-29 2007-01-31 Duphar Int Res Piperazine and piperidine compounds
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
AR034206A1 (en) 2001-02-16 2004-02-04 Solvay Pharm Bv A PROCEDURE FOR THE PREPARATION OF MESILATES OF PIPERAZINE DERIVATIVES AND SUCH MESILATES
AR045362A1 (en) * 2003-08-18 2005-10-26 Solvay Pharm Bv STABLE CRYSTALLINE FORM OF BIFEPRUNOX MESILATE (MONOMETANSULFONATE 7- [4 - ([1,1- BIFENIL] -3- ILMETIL) -1- PIPERAZINIL] - 2- (3H) -BENZOXAZOLONA
US7423040B2 (en) * 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
PT1919883E (en) 2005-08-22 2009-03-26 Solvay Pharm Bv N-oxides as prodrugs of piperazine&piperidine derivatives

Also Published As

Publication number Publication date
WO2008025780A1 (en) 2008-03-06
IL196867A0 (en) 2009-11-18
CA2661120A1 (en) 2008-03-06
JP2010501625A (en) 2010-01-21
AU2007291235A1 (en) 2008-03-06
EP2059245A1 (en) 2009-05-20
AU2007291234A1 (en) 2008-03-06
BRPI0715445A2 (en) 2014-05-13
WO2008025781A1 (en) 2008-03-06
JP2010501626A (en) 2010-01-21
CA2661800A1 (en) 2008-03-06
EP2059244A1 (en) 2009-05-20
NO20091243L (en) 2009-03-25
KR20090063228A (en) 2009-06-17

Similar Documents

Publication Publication Date Title
EA200970239A1 (en) TITING REGIME OF BIFEPRUNOX FOR THE TREATMENT OF SCHIZOPHRENIA AND KITS FOR APPLICATION IN THIS AREA
WO2008056259A3 (en) Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
DE602007009420D1 (en) OXADIAZOL DERIVATIVES AS S1P1 RECEPTOR AGONISTS
MA31906B1 (en) HIV inhibitors
EA200702498A1 (en) N- (PYRIDIN-2-IL) SULPHONAMIDE DERIVATIVES
MA31419B1 (en) PYRIDINE DERIVATIVES
CL2007002899A1 (en) Compounds derived from n-substituted azacyclylamines, histamine 3 receptor inhibitors; Preparation process; pharmaceutical composition comprising the compounds, and use for the treatment of cognitive disorders, schizophrenia and Alzheimer's disease among others.
EA200901373A1 (en) AMINOGETEROCYCLIC COMPOUNDS
MA31683B1 (en) Fxr modulation components and methods
TN2010000175A1 (en) SUBSTITUTED PIPERIDINO-DIHYDROTHIENOPYRIMIDINES
MA30911B1 (en) NOVEL SULFONAMIDE DERIVATIVES AS BRADYKININE ANTAGONISTS
BRPI0510177B8 (en) compound, pharmaceutical composition and use thereof
PE20081441A1 (en) SUBTYPE OF SELECTIVE AMIDAS OF DIAZABICICLOALKANES
MA30765B1 (en) INNOVATIVE DERIVATIVES OF THIOPHENE
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
EA200870380A1 (en) AMINOTETRAHYDROPYRANE AS DIPEPTIDYLPEPTIDASE-VI INHIBITORS FOR TREATMENT OR PREVENTION OF DIABETES
MA30652B1 (en) ORGANIC COMPOUNDS
NO20076479L (en) New oxadiazole derivatives and their use as positive allosteric metabotropic modulators of glutamate receptors
MA31158B1 (en) Tricyclic compounds and their use as modifiers for glucocorticoid receptors.
MA30916B1 (en) NOVEL BENZAMIDE DERIVATIVES AS BRADYKININE ANTAGONISTS
EA200701594A1 (en) LAKOSAMID FOR ADDITIONAL THERAPY
UA112055C2 (en) SALTS 4- [2 - [[5-METHYL-1- (2-NAPHTHALINYL) -1H-PYRAZOL-3-yl] OXY] ETHYL] MORPHOLINE
BRPI0518993A2 (en) compound or a pharmaceutically acceptable salt, solvate or ester thereof, pharmaceutical composition, and use of a compound
MA38315B1 (en) Heterocycle-substituted tetracyclic compounds and methods for their use in the treatment of viral diseases
UY29995A1 (en) USE OF A CB1 ANTAGONIST TO TREAT SECONDARY EFFECTS AND NEGATIVE SYMPTOMS OF CHICHOPHRENIA